Article

Heidelberg Engineering expands Spectralis product line

Heidelberg Engineering GmbH expands its line of Spectralis retinal imaging products by adding a more economical two-mode, spectral domain-optical coherence tomography (SD-OCT) technology. The expanded family now consists of Spectralis OCT (two modes); Spectralis HRA (five modes); and Spectralis HRA+OCT (six modes).

Heidelberg Engineering GmbH expands its line of Spectralis retinal imaging products by adding a more economical two-mode, spectral domain-optical coherence tomography (SD-OCT) technology. The expanded family now consists of Spectralis OCT (two modes); Spectralis HRA (five modes); and Spectralis HRA+OCT (six modes).

Spectralis OCT offers two imaging modes (SD-OCT and infrared), while the Spectralis HRA+OCT includes four additional imaging modes (autofluorescence, red-free imaging, fluorescein angiography, and ICG angiography). The new model shares three key features with the earlier version: 40,000 A-scans per second, TruTrack eye-tracking technology, and Heidelberg noise reduction (HNR) for image clarity.

The Spectralis instrument captures the OCT cross-sectional scan under constant guidance of one of five fundus imaging modalities. This helps ensure image registration and enables the instruments to track change precisely over time, an advantage over the technical limitations of time-domain OCT, according to the company. In addition, HNR technology significantly improves image quality by eliminating unwanted optical noise in both fundus and OCT images.

Shipment of the product is expected to begin this summer, according to the company.

For more information, visit Heidelberg Engineering at Booth 1541.

Related Videos
(Image credit: Ophthalmology Times) Neda Shamie_Controversies in Modern Eye Care 2025
(Image credit: Ophthalmology Times) World Cornea Congress IX: Epi-on and accelerated crosslinking with Kenneth Beckman, MD
(Image credit: Ophthalmology Times) The synergy of cornea, cataract, and refractive surgery through the decades: insights from George O. Waring IV, MD
(Image credit: Ophthalmology Times) AGS 2025: A look at Gemini and the MIGS revolution with Mona Kaleem, MD
(Image credit: Ophthalmology Times) AGS 2025: Development and evaluation of an AI model to set target IOP with Jithin Yohannan, MD, MPH
(Image credit: Ophthalmology Times) NeuroOp Guru: The role of muscle biopsy in heteroplasmy detection
© 2025 MJH Life Sciences

All rights reserved.